(300 WORDS MAX.)Two principle drivers of Alzheimer's disease progression are believed to be excessive glutamate signaling and neuroinflammation. The glutamate pathway has been clinically validated in Alzheimer's, with memantine, an inhibitor of glutamate signaling, currently one of the few approved therapies. Glialogix is repositioning and reformulating an FDA-approved drug to antagonize a novel target in the glutamate pathway for treatment of neurodegenerative diseases. Our therapeutic strategy is intended to prevent further neuronal damage by inhibiting excessive glutamate signaling and attenuating levels of neuroinflammation, specifically activated microglia and astrocytes.